Theranexus Société Anonyme Past Earnings Performance
Past criteria checks 0/6
Theranexus Société Anonyme's earnings have been declining at an average annual rate of -6.4%, while the Pharmaceuticals industry saw earnings growing at 15.3% annually. Revenues have been declining at an average rate of 8% per year.
Key information
-6.4%
Earnings growth rate
7.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 16.3% |
| Revenue growth rate | -8.0% |
| Return on equity | -259.0% |
| Net Margin | -2,140.4% |
| Next Earnings Update | 26 Sep 2024 |
Revenue & Expenses BreakdownBeta
How Theranexus Société Anonyme makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -7 | 3 | 0 |
| 30 Sep 23 | 0 | -7 | 3 | 0 |
| 30 Jun 23 | 0 | -7 | 3 | 0 |
| 31 Mar 23 | 0 | -7 | 3 | 0 |
| 31 Dec 22 | 0 | -7 | 3 | 0 |
| 30 Sep 22 | 0 | -7 | 3 | 0 |
| 30 Jun 22 | 0 | -8 | 3 | 0 |
| 31 Mar 22 | 0 | -8 | 3 | 0 |
| 31 Dec 21 | 0 | -8 | 3 | 0 |
| 30 Sep 21 | 0 | -7 | 3 | 0 |
| 30 Jun 21 | 0 | -6 | 3 | 0 |
| 31 Mar 21 | 0 | -5 | 3 | 0 |
| 31 Dec 20 | 0 | -5 | 3 | 0 |
| 30 Sep 20 | 0 | -5 | 2 | 0 |
| 30 Jun 20 | 0 | -6 | 2 | 0 |
| 31 Mar 20 | 0 | -6 | 2 | 0 |
| 31 Dec 19 | 1 | -6 | 2 | 0 |
| 30 Sep 19 | 1 | -6 | 2 | 0 |
| 30 Jun 19 | 1 | -6 | 2 | 0 |
| 31 Mar 19 | 0 | -6 | 2 | 0 |
| 31 Dec 18 | 0 | -5 | 2 | 0 |
| 30 Sep 18 | 0 | -4 | 2 | 0 |
| 30 Jun 18 | 0 | -3 | 2 | 0 |
| 31 Mar 18 | 0 | -3 | 2 | 0 |
| 31 Dec 17 | 0 | -2 | 1 | 0 |
| 30 Sep 17 | 0 | -2 | 1 | 0 |
| 30 Jun 17 | 0 | -2 | 1 | 0 |
| 31 Mar 17 | 0 | -2 | 1 | 0 |
| 31 Dec 16 | 0 | -2 | 1 | 0 |
| 31 Dec 15 | 1 | -1 | 1 | 0 |
Quality Earnings: ALTHX is currently unprofitable.
Growing Profit Margin: ALTHX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ALTHX is unprofitable, and losses have increased over the past 5 years at a rate of 6.4% per year.
Accelerating Growth: Unable to compare ALTHX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ALTHX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.5%).
Return on Equity
High ROE: ALTHX has a negative Return on Equity (-258.96%), as it is currently unprofitable.